Eli Lilly and Company (LLY) to Acquire Ventyx Biosciences
Eli Lilly and Company (NYSE:LLY) is one of the best performing pharma stocks in 2025.
Eli Lilly & Co (LLY)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Fisher Asset Management Ken Fisher | 4,453,062 | $3,397,687,594 | +4% | 1.23% |
| 2. | 2,327,200 | $1,775,653,600 | -38% | 0.27% | |
| 3. | 2,229,400 | $1,701,032,200 | +30% | 0.26% | |
| 4. | Citadel Investment Group Ken Griffin | 1,152,818 | $879,600,134 | +36% | 0.13% |
| 5. | Adage Capital Management Phill Gross And Robert Atchinson | 806,866 | $615,638,758 | -5% | 0.98% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $691.79 | 715 | $494,626.99 | 14,685 | 2025-08-15 | Filing | |
| $660.25 | 758 | $500,472.53 | 758 | 2025-08-13 | Filing | |
| $647.36 | 1,000 | $647,360.00 | 20,562 | 2025-08-13 | Filing | |
| $644.77 | 1,632 | $1,052,263.01 | 546,601 | 2025-08-12 | Filing | |
| $634.41 | 1,000 | $634,405.00 | 137,660 | 2025-08-12 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1,116.69 | 2,737 | $3,056,369.58 | 91,896,978 | 2026-01-07 | Filing | |
| $1,115.76 | 2,210 | $2,465,831.81 | 91,899,715 | 2026-01-07 | Filing | |
| $1,114.37 | 4,342 | $4,838,603.22 | 91,901,925 | 2026-01-07 | Filing | |
| $1,113.77 | 9,053 | $10,082,968.86 | 91,906,267 | 2026-01-07 | Filing | |
| $1,112.43 | 4,652 | $5,175,038.32 | 91,915,320 | 2026-01-07 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,479,977 | $1,594,971,213 | 1.37% | |
| 2. | 341,724 | $367,243,948 | 0.51% | |
| 3. | 213,986 | $228,150,900 | 0.31% | |
| 4. | 131,497 | $141,317,198 | 1.47% | |
| 5. | 84,298 | $92,476,612 | 1.1% |
News See All
10 Best Performing Pharma Stocks in 2025
On January 8, Michael Yee, global head of biotech research at UBS, appeared on CNBC’s ‘Squawk on the Street’ to discuss his bullish outlook on biopharma stocks in 2026 and the pharma M&A outlook...
ClearBridge Large Cap Growth Strategy’s Thoughts on Eli Lilly and Company (LLY)
ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” fourth-quarter 2025 investor letter.
12 Best Unstoppable Growth Stocks to Buy Right Now
On January 6, Brad Gerstner, the founder and CEO of Altimeter Capital, appeared on a CNBC Television interview to talk about how he is positioning his portfolio for 2026.
What Makes Eli Lilly And Co. (LLY) a Worthy Holding?
Alpha Wealth Funds, LLC, an investment management company, released its Q3 2025 letter for the “Insiders Fund”. A copy of the letter can be downloaded here.
Eli Lilly (LLY) Moves Fast to Secure Lead in India’s Obesity Drug Market
Eli Lilly and Company (NYSE:LLY) is moving quickly to lock in its position in India’s fast-growing obesity drug market.
14 Best Pharma Dividend Stocks to Buy in 2026
For most drugmakers, the US is the largest single market. Prices there are often close to three times higher than in other developed countries. Branded medicines carry even steeper premiums.
Jim Cramer Answered Questions About These 11 Stocks
“What really mattered today, though, is the possibility that funding for the data center build-out, something that was beginning to seem chimerical, has tantalizingly returned to a degree of certainty...
Jim Cramer Discusses Major Catalyst For Eli Lilly (LLY)
Eli Lilly and Company (NYSE:LLY) is another top Cramer healthcare stock.
BofA Maintains Buy on Eli Lilly (LLY), Expects 2027 Earnings to Fully Realize Value of Obesity Drug Launches
Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy in 2026.
Hedge Fund Resource Center Billionaire Hedge Funds
